Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks

References

• Widimský P, Kožnar B, Vaško P, Peisker T, Štětkářová I. Acute myocardial infarction and acute stroke: What are the differences? Focus on reperfusion therapy. Cor Vasa 2013; 55:e111-6; https://doi.org/10.1016/j.crvasa.2013.02.002
   Google Scholar
• Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke: Platelet adhesion and activation mechanisms. J Thromb Haemost 2011; 9:92-104; PMID:21781245; https://doi.org/10.1111/j.1538-7836.2011.04361.x
   PubMed Web of Science ®Google Scholar
• McFadyen JD, Jackson SP. Differentiating haemostasis from thrombosis for therapeutic benefit. Thromb Haemost 2013; 110:859-67; PMID:23945664; https://doi.org/10.1160/TH13-05-0379
   PubMed Web of Science ®Google Scholar
• Gachet C. Antiplatelet drugs: Which targets for which treatments? J Thromb Haemost 2015; 13:S313-22; PMID:26149041; https://doi.org/10.1111/jth.12947
   PubMed Web of Science ®Google Scholar
• Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2014; 12:30-47; PMID:25286881; https://doi.org/10.1038/nrcardio.2014.156
   PubMed Web of Science ®Google Scholar
• Thachil J. Antiplatelet therapy - a summary for the general physicians. Clin Med Lond Engl 2016; 16:152-60; PMID:27037385; https://doi.org/10.7861/clinmedicine.16-2-152
   PubMed Web of Science ®Google Scholar
• Coutinho JM, Liebeskind DS, Slater L-A, Nogueira RG, Clark W, Dávalos A, Bonafé A, Jahan R, Fischer U, Gralla J, et al. Combined Intravenous Thrombolysis and Thrombectomy vs Thrombectomy Alone for Acute Ischemic Stroke: A Pooled Analysis of the SWIFT and STAR Studies. JAMA Neurol 2017; 74:268-74; PMID:28097310; https://doi.org/10.1001/jamaneurol.2016.5374
   PubMed Web of Science ®Google Scholar
• Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102:449-61; PMID:12649139; https://doi.org/10.1182/blood-2002-12-3882
   PubMed Web of Science ®Google Scholar
• Jiang P, Jandrot-Perrus M. New advances in treating thrombotic diseases: GPVI as a platelet drug target. Drug Discov Today 2014; 19:1471-5; PMID:24931218; https://doi.org/10.1016/j.drudis.2014.06.005
   PubMed Web of Science ®Google Scholar
• Induruwa I, Jung SM, Warburton EA. Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke. Int J Stroke Off J Int Stroke Soc 2016; 11:618-25; PMID:27312676; https://doi.org/10.1177/1747493016654532
   PubMed Web of Science ®Google Scholar
• Mammadova-Bach E, Ollivier V, Loyau S, Schaff M, Dumont B, Favier R, Freyburger G, Latger-Cannard V, Nieswandt B, Gachet C, et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood 2015; 126:683-91; PMID:25977585; https://doi.org/10.1182/blood-2015-02-629717
   PubMed Web of Science ®Google Scholar
• Dumont B, Lasne D, Rothschild C, Bouabdelli M, Ollivier V, Oudin C, Ajzenberg N, Grandchamp B, Jandrot-Perrus M. Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations. Blood 2009; 114:1900-3; PMID:19549989; https://doi.org/10.1182/blood-2009-03-213504
   PubMed Web of Science ®Google Scholar
• Takahashi H, Moroi M. Antibody against platelet membrane glycoprotein VI in a patient with systemic lupus erythematosus. Am J Hematol 2001; 67:262-7; PMID:11443641; https://doi.org/10.1002/ajh.1128
   PubMed Web of Science ®Google Scholar
• Bhunia SS, Misra A, Khan IA, Gaur S, Jain M, Singh S, Saxena A, Hohlfield T, Dikshit M, Saxena AK. Novel glycoprotein VI antagonists as antithrombotics: synthesis, biological evaluation, and molecular modeling studies on 2,3-disubstituted tetrahydropyrido(3,4-b)indoles. J Med Chem 2017; 60:322-37; PMID:27996269; https://doi.org/10.1021/acs.jmedchem.6b01360
   PubMed Web of Science ®Google Scholar
• Reimann A, Li Z, Goebel S, Fassbender J, Holthoff H-P, Gawaz M, Münch G, Ungerer M. Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke. Heart Int 2016; 11:e10-6; PMID:27924212; https://doi.org/10.5301/heartint.5000229
   PubMed Web of Science ®Google Scholar
• Li H, Lockyer S, Concepcion A, Gong X, Takizawa H, Guertin M, Matsumoto Y, Kambayashi J, Tandon NN, Liu Y. The fab fragment of a novel Anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. Arterioscler Thromb Vasc Biol 2007; 27:1199-205; PMID:17322098; https://doi.org/10.1161/ATVBAHA.107.140590
   PubMed Web of Science ®Google Scholar
• Takayama H, Hosaka Y, Nakayama K, Shirakawa K, Naitoh K, Matsusue T, Shinozaki M, Honda M, Yatagai Y, Kawahara T, et al. A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J Clin Invest 2008; 118:1785-95; PMID:18382762; https://doi.org/10.1172/JCI32513
   PubMed Web of Science ®Google Scholar
• Lecut C, Feeney LA, Kingsbury G, Hopkins J, Lanza F, Gachet C, Villeval J-L, Jandrot-Perrus M. Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. J Thromb Haemost JTH 2003; 1:2653-62; PMID:14675102; https://doi.org/10.1111/j.1538-7836.2003.00495.x
   PubMed Web of Science ®Google Scholar
• Jamasbi J, Megens RTA, Bianchini M, Münch G, Ungerer M, Faussner A, Sherman S, Walker A, Goyal P, Jung S, et al. Differential inhibition of human atherosclerotic plaque-induced platelet activation by dimeric GPVI-Fc and Anti-GPVI antibodies: Functional and imaging studies. J Am Coll Cardiol 2015; 65:2404-15; PMID:26046734; https://doi.org/10.1016/j.jacc.2015.03.573
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Takizawa H, Gong X, Le S, Lockyer S, Okuyama K, Tanaka M, Yoshitake M, Tandon NN, Kambayashi J. Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization. Thromb Res 2007; 119:319-29; PMID:16566959; https://doi.org/10.1016/j.thromres.2006.01.023
   PubMed Web of Science ®Google Scholar
• Smethurst PA, Joutsi-Korhonen L, O'Connor MN, Wilson E, Jennings NS, Garner SF, Zhang Y, Knight CG, Dafforn TR, Buckle A, et al. Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood 2004; 103:903-11; PMID:14504096; https://doi.org/10.1182/blood-2003-01-0308
   PubMed Web of Science ®Google Scholar
• Muzard J, Bouabdelli M, Zahid M, Ollivier V, Lacapère JJ, Jandrot-Perrus M, Billiald P. Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro. FEBS J 2009; 276:4207-22; PMID:19558491; https://doi.org/10.1111/j.1742-4658.2009.07129.x
   PubMed Web of Science ®Google Scholar
• Mangin PH, Tang C, Bourdon C, Loyau S, Freund M, Hechler B, Gachet C, Jandrot-Perrus M. A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents. J Pharmacol Exp Ther 2012; 341:156-63; PMID:22238212; https://doi.org/10.1124/jpet.111.189050
   PubMed Web of Science ®Google Scholar
• Léger O, Saldanha JW. Humanization of antibodies. In: Antibody drug discovery. Wood C.R; Imperial College Press 2011; 492.
   Google Scholar
• Kabat EA. The structural basis of antibody complementarity. Adv Protein Chem 1978; 32:1-75. PMID:362869; https://doi.org/10.1186/1471-2164-5-12
   PubMedGoogle Scholar
• Kabat EA, Wu TT, Bilofsky H. Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites. J Biol Chem 1977; 252:6609-16. PMID:408353; https://doi.org/10.1172/jc15118
   PubMed Web of Science ®Google Scholar
• Kabat EA, Wu TT. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol Baltim Md 1950 1991; 147:1709-19; PMID:1908882
   PubMed Web of Science ®Google Scholar
• Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G. Structural repertoire of the human VH segments. J Mol Biol 1992; 227:799-817; PMID:1404389; https://doi.org/10.1016/0022-2836(92)90224-8
   PubMed Web of Science ®Google Scholar
• Chothia C, Novotný J, Bruccoleri R, Karplus M. Domain association in immunoglobulin molecules. The packing of variable domains. J Mol Biol 1985; 186:651-63; PMID:4093982
   PubMed Web of Science ®Google Scholar
• Muzard J, Adi-Bessalem S, Juste M, Laraba-Djebari F, Aubrey N, Billiald P. Grafting of protein L-binding activity onto recombinant antibody fragments. Anal Biochem 2009; 388:331-8; PMID:19268418; https://doi.org/10.1016/j.ab.2009.02.035
   PubMed Web of Science ®Google Scholar
• Lakhrif Z, Pugnière M, Henriquet C, di Tommaso A, Dimier-Poisson I, Billiald P, Juste MO, Aubrey N. A method to confer Protein L binding ability to any antibody fragment. mAbs 2016; 8:379-88; PMID:26683650; https://doi.org/10.1080/19420862.2015.1116657
   PubMed Web of Science ®Google Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36; PMID:16151406; https://doi.org/10.1038/nbt1142
   PubMed Web of Science ®Google Scholar
• Ohlmann P, Hechler B, Ravanat C, Loyau S, Herrenschmidt N, Wanert F, Jandrot-Perrus M, Gachet C. Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression. J Thromb Haemost JTH 2008; 6:1003-11; PMID:18419749; https://doi.org/10.1111/j.1538-7836.2008.02976.x
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-7; PMID:3127726; https://doi.org/10.1038/332323a0
   PubMed Web of Science ®Google Scholar
• Mahler H-C, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci 2009; 98:2909-34; PMID:18823031; https://doi.org/10.1002/jps.21566
   PubMed Web of Science ®Google Scholar
• Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, Narhi LO, Topp EM. Immunogenicity of therapeutic protein aggregates. J Pharm Sci 2016; 105:417-30; PMID:26869409; https://doi.org/10.1016/j.xphs.2015.11.002
   PubMed Web of Science ®Google Scholar
• Kaleas KA, Tripodi M, Revelli S, Sharma V, Pizarro SA. Evaluation of a multimodal resin for selective capture of CHO-derived monoclonal antibodies directly from harvested cell culture fluid. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 969:256-63; PMID:25203722; https://doi.org/10.1016/j.jchromb.2014.08.026
   PubMed Web of Science ®Google Scholar
• Rodrigo G, Gruvegård M, Van Alstine J. Antibody fragments and their purification by protein L affinity chromatography. Antibodies 2015; 4:259-77; https://doi.org/10.3390/antib4030259
   Web of Science ®Google Scholar
• Arora S, Saxena V, Ayyar BV. Affinity chromatography: A versatile technique for antibody purification. Methods 2017; 116:84-94; PMID:28012937; https://doi.org/10.1016/j.ymeth.2016.12.010
   PubMed Web of Science ®Google Scholar
• De Groot AS, Martin W. Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics. Clin Immunol 2009; 131:189-201; PMID:19269256; https://doi.org/10.1016/j.clim.2009.01.009
   PubMed Web of Science ®Google Scholar
• Nieswandt B, Schulte V, Bergmeier W, Mokhtari-Nejad R, Rackebrandt K, Cazenave JP, Ohlmann P, Gachet C, Zirngibl H. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 2001; 193:459-69; PMID:11181698; https://doi.org/10.1084/jem.193.4.459
   PubMed Web of Science ®Google Scholar
• Simoons ML, GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet Lond Engl 2001; 357:1915-24; PMID:11425411; https://doi.org/10.1016/S0140-6736(00)05060-1
   PubMed Web of Science ®Google Scholar
• Harris D, Hall C, Lobay K, McRae A, Monroe T, Perry JJ, Shearing A, Wollam G, Goddard T, Lang E. Canadian association of emergency physicians position statement on acute ischemic stroke. CJEM 2015; 17:217-26; PMID:26120643; https://doi.org/10.1017/cem.2015.26
   PubMedGoogle Scholar
• Jandrot-Perrus M, Busfield S, Lagrue AH, Xiong X, Debili N, Chickering T, Le Couedic JP, Goodearl A, Dussault B, Fraser C, et al. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: A platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 2000; 96:1798-807. PMID:10961879
   PubMed Web of Science ®Google Scholar
• Appel RD, Bairoch A, Hochstrasser DF. A new generation of information retrieval tools for biologists: The example of the ExPASy WWW server. Trends Biochem Sci 1994; 19:258-60; PMID:8073505; https://doi.org/10.1016/0968-0004(94)90153-8
   PubMed Web of Science ®Google Scholar
• Abhinandan KR, Martin ACR. Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains. Mol Immunol 2008; 45:3832-9; PMID:18614234; https://doi.org/10.1016/j.molimm.2008.05.022
   PubMed Web of Science ®Google Scholar
• Marcatili P, Rosi A, Tramontano A. PIGS: Automatic prediction of antibody structures. Bioinforma Oxf Engl 2008; 24:1953-4; PMID:18641403; https://doi.org/10.1093/bioinformatics/btn341
   PubMed Web of Science ®Google Scholar
• Ehrenmann F. Lefranc M-P. IMGT/DomainGapAlign: IMGT standardized analysis of amino acid sequences of variable, constant, and groove domains (IG, TR, MH, IgSF, MhSF). Cold Spring Harb Protoc 2011; 2011:737-49. PMID:21632775
   PubMedGoogle Scholar
• Chothia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 1987; 196:901-17; PMID:3681981; https://doi.org/10.1016/0022-2836(87)90412-8
   PubMed Web of Science ®Google Scholar
• North B, Lehmann A, Dunbrack RL. A new clustering of antibody CDR loop conformations. J Mol Biol 2011; 406:228-56; PMID:21035459; https://doi.org/10.1016/j.jmb.2010.10.030
   PubMed Web of Science ®Google Scholar
• Abhinandan KR, Martin ACR. Analysis and prediction of VH/VL packing in antibodies. Protein Eng Des Sel PEDS 2010; 23:689-97; PMID:20591902; https://doi.org/10.1093/protein/gzq043
   PubMed Web of Science ®Google Scholar
• Honegger A, Plückthun A. Yet another numbering scheme for immunoglobulin variable domains: An automatic modeling and analysis tool. J Mol Biol 2001; 309:657-70; PMID:11397087; https://doi.org/10.1006/jmbi.2001.4662
   PubMed Web of Science ®Google Scholar
• Abhinandan KR, Martin ACR. Analyzing the “degree of humanness” of antibody sequences. J Mol Biol 2007; 369:852-62; PMID:17442342; https://doi.org/10.1016/j.jmb.2007.02.100
   PubMed Web of Science ®Google Scholar
• Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol Baltim Md 1950 1994; 152:163-75; PMID:8254189
   PubMed Web of Science ®Google Scholar
• Menzen T, Friess W. High-throughput melting-temperature analysis of a monoclonal antibody by differential scanning fluorimetry in the presence of surfactants. J Pharm Sci 2013; 102:415-28; PMID:23212746; https://doi.org/10.1002/jps.23405
   PubMed Web of Science ®Google Scholar
• Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol Baltim Md 1950 1998; 160:3363-73; PMID:9531296
   PubMed Web of Science ®Google Scholar